These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23065020)

  • 1. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.
    Campanati A; Ganzetti G; Di Sario A; Damiani A; Sandroni L; Rosa L; Benedetti A; Offidani A
    J Gastroenterol; 2013 Jul; 48(7):839-46. PubMed ID: 23065020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.
    Ortolan A; Lorenzin M; Tadiotto G; Russo FP; Oliviero F; Felicetti M; D'Incà R; Favero M; Piaserico S; Doria A; Ramonda R
    Clin Rheumatol; 2019 Oct; 38(10):2843-2850. PubMed ID: 31254236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients.
    Neagoe CD; Farmazon AS; Amzolini AM; Singer CE; Ianoşi SL; Tutunaru CV; Genunche-Dumitrescu AV; Ianoşi NG; Păun I; Leru PM; Tica OS; Popescu M
    Rom J Morphol Embryol; 2020; 61(2):503-511. PubMed ID: 33544802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Bugianesi E; Bouserhal T; Marini F; Ridolfi F; Tarsetti F; Ancarani F; Petrelli E; Peruzzi E; Lo Cascio M; Rizzetto M; Marchesini G; Benedetti A
    Gut; 2007 Sep; 56(9):1296-301. PubMed ID: 17392334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
    Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
    Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of etanercept on insulin sensitivity in nine patients with psoriasis.
    Marra M; Campanati A; Testa R; Sirolla C; Bonfigli AR; Franceschi C; Marchegiani F; Offidani A
    Int J Immunopathol Pharmacol; 2007; 20(4):731-6. PubMed ID: 18179745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective.
    Jones-Caballero M; Unaeze J; Peñas PF; Stern RS
    Arch Dermatol; 2007 Jul; 143(7):846-50. PubMed ID: 17638727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment.
    Puig L; Strohal R; Fuiman J; Pedersen R; Szumski A; Koenig AS; Robertson D; Drexel H
    J Dermatolog Treat; 2014 Dec; 25(6):470-81. PubMed ID: 24219012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients.
    Belinchón-Romero I; Bellot P; Romero-Pérez D; Herraiz-Romero I; Marco F; Frances R; Ramos-Rincón JM
    Sci Rep; 2021 Apr; 11(1):8593. PubMed ID: 33883616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children?
    Fu JF; Shi HB; Liu LR; Jiang P; Liang L; Wang CL; Liu XY
    World J Gastroenterol; 2011 Feb; 17(6):735-42. PubMed ID: 21390143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
    Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
    Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease.
    Fujii H; Imajo K; Yoneda M; Nakahara T; Hyogo H; Takahashi H; Hara T; Tanaka S; Sumida Y; Eguchi Y; Chayama K; Nakajima A; Nishimoto N; Kawada N;
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1390-1395. PubMed ID: 30600551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis and Nonalcoholic Fatty Liver Disease.
    Carrascosa JM; Bonanad C; Dauden E; Botella R; Olveira-Martín A;
    Actas Dermosifiliogr; 2017; 108(6):506-514. PubMed ID: 28318525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease.
    Bajaj S; Nigam P; Luthra A; Pandey RM; Kondal D; Bhatt SP; Wasir JS; Misra A
    Indian J Med Res; 2009 Mar; 129(3):285-92. PubMed ID: 19491421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.
    Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC
    Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.